A big STEP for treatment of heart failure with preserved ejection fraction

Subodh Verma; Barry A. Borlaug; Javed Butler; Melanie J. Davies; Dalane W. Kitzman; Mark C. Petrie; Sanjiv J. Shah; Nitish K. Dhingra; Mikhail N. Kosiborod

doi:10.1016/j.cmet.2023.08.003

A big STEP for treatment of heart failure with preserved ejection fraction

Subodh Verma^*, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Mark C. Petrie, Sanjiv J. Shah, Nitish K. Dhingra, Mikhail N. Kosiborod^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

Original language	English (US)
Pages (from-to)	1681-1687
Number of pages	7
Journal	Cell Metabolism
Volume	35
Issue number	10
DOIs	https://doi.org/10.1016/j.cmet.2023.08.003
State	Published - Oct 3 2023

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cmet.2023.08.003

Cite this

@article{4fdd1e57fd9542fb86375cb7be2cb40d,

title = "A big STEP for treatment of heart failure with preserved ejection fraction",

abstract = "In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.",

author = "Subodh Verma and Borlaug, {Barry A.} and Javed Butler and Davies, {Melanie J.} and Kitzman, {Dalane W.} and Petrie, {Mark C.} and Shah, {Sanjiv J.} and Dhingra, {Nitish K.} and Kosiborod, {Mikhail N.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = oct,

day = "3",

doi = "10.1016/j.cmet.2023.08.003",

language = "English (US)",

volume = "35",

pages = "1681--1687",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "10",

}

TY - JOUR

T1 - A big STEP for treatment of heart failure with preserved ejection fraction

AU - Verma, Subodh

AU - Borlaug, Barry A.

AU - Butler, Javed

AU - Davies, Melanie J.

AU - Kitzman, Dalane W.

AU - Petrie, Mark C.

AU - Shah, Sanjiv J.

AU - Dhingra, Nitish K.

AU - Kosiborod, Mikhail N.

PY - 2023/10/3

Y1 - 2023/10/3

N2 - In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

AB - In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=85170548094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170548094&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2023.08.003

DO - 10.1016/j.cmet.2023.08.003

M3 - Comment/debate

C2 - 37643614

AN - SCOPUS:85170548094

SN - 1550-4131

VL - 35

SP - 1681

EP - 1687

JO - Cell Metabolism

JF - Cell Metabolism

IS - 10

ER -

A big STEP for treatment of heart failure with preserved ejection fraction

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this